Fulcrum Therapeutics (NASDAQ:FULC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Fulcrum reported Q1 EPS of ($0.25), beating the consensus estimate of ($0.31) by $0.06.
• Phase Ib PIONEER data showed 20 mg once‑daily pociredir raised mean fetal hemoglobin from 7.1% to 19.3% at 12 weeks, improved hemolysis and anemia markers, and saw seven of 12 patients with no VOCs and no treatment‑related serious adverse events; the company plans an end‑of‑phase FDA meeting this quarter and is targeting a potential registration‑enabling study in H2 2026 pending feedback.
• Fulcrum ended Q1 with $333.3 million in cash and marketable securities, which management says provides runway into 2029, but the open‑label long‑term dosing study just began enrollment so meaningful longer‑term safety and durability data are unlikely before 2027.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) issued its earnings results on Monday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06, Zacks reports.

Here are the key takeaways from Fulcrum Therapeutics' conference call:

• Phase Ib PIONEER data showed that 20 mg once-daily pociredir increased mean fetal hemoglobin (HbF) from 7.1% to 19.3% at 12 weeks, improved hemolysis and anemia markers, and seven of 12 patients experienced no VOCs, with no treatment-related serious adverse events reported.
• Fulcrum plans an end-of-phase meeting with the FDA this quarter and expects to provide a trial design update, targeting initiation of a potential registration‑enabling study in the second half of 2026 pending FDA feedback.
• The company ended Q1 with $333.3 million in cash and marketable securities, which management says provides financial runway into 2029 to advance pociredir through the next development stages.
• The open‑label long‑term dosing study has only just enrolled its first patient and faces site activation and roll‑over limitations, so robust longer‑term safety and durability data are unlikely to be available before 2027.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC opened at $7.72 on Tuesday. The firm's 50-day moving average price is $8.06 and its 200-day moving average price is $9.55. The company has a market capitalization of $514.15 million, a PE ratio of -6.54 and a beta of 3.27. Fulcrum Therapeutics has a 1-year low of $3.45 and a 1-year high of $15.74.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its position in shares of Fulcrum Therapeutics by 236.8% in the 4th quarter. Invesco Ltd. now owns 417,189 shares of the company's stock worth $4,718,000 after buying an additional 293,317 shares during the period. XTX Topco Ltd purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $586,000. Ikarian Capital LLC grew its position in shares of Fulcrum Therapeutics by 6.7% in the 4th quarter. Ikarian Capital LLC now owns 1,375,472 shares of the company's stock worth $15,557,000 after buying an additional 86,247 shares during the period. Vestal Point Capital LP purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $10,744,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $231,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

FULC has been the topic of several analyst reports. Truist Financial set a $17.00 target price on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. JPMorgan Chase & Co. initiated coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an "overweight" rating and a $20.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday, April 12th. Finally, Leerink Partners reaffirmed an "outperform" rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Fulcrum Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $19.00.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.